Journal Homepage: www.ijrpr.com ISSN: 3049-0103 (Online)

International Journal of Advance Research Publication and Reviews

Vol 02, Issue 06, pp 351-375, June 2025

Spatial Transcriptomics in Surgical Pathology: Resolving Tumor Microenvironment Architecture in Formalin-Fixed Tissue Sections

Ebenezer Amarachukwu Okoh

Department of Pathology and Laboratory Medicine, Delta State University Teaching Hospital, Oghara, Delta State, Nigeria
DOI : https://doi.org/10.55248/gengpi.6.0625.2267

ABSTRACT

The tumor microenvironment (TME) is increasingly recognized as a key driver of oncogenesis, therapeutic resistance, and disease progression. Understanding the spatial relationships between neoplastic cells and stromal, immune, and vascular components has become essential for both research and clinical pathology. However, conventional histology and bulk transcriptomic analyses fail to resolve gene expression patterns with spatial fidelity, especially in archived formalin-fixed, paraffin-embedded (FFPE) specimens that constitute the bulk of diagnostic tissue repositories. Recent advances in spatial transcriptomics now enable the simultaneous measurement of gene expression and spatial localization at near single-cell resolution, directly within intact tissue sections. This transformative methodology allows pathologists to preserve architectural context while accessing high-dimensional molecular data, offering new insights into tumor heterogeneity, immune infiltration patterns, and stromal remodeling. Crucially, emerging spatial transcriptomics platforms have adapted to FFPE-compatible workflows, overcoming previous limitations associated with RNA degradation and crosslinking artifacts. This review explores the integration of spatial transcriptomics into surgical pathology, with emphasis on FFPE-validated protocols, clinical feasibility, and interpretive value. We discuss current platforms (e.g., 10x Genomics Visium, NanoString GeoMx DSP), bioinformatic pipelines for spatially resolved transcriptomic data, and real-world applications in tumor phenotyping, biomarker discovery, and therapeutic stratification. Case studies demonstrate how spatial transcriptomics resolves spatial immune gradients in immune checkpoint inhibitor response and delineates invasive margins in solid tumors. By embedding high-dimensional data into familiar histopathologic workflows, spatial transcriptomics is poised to augment precision diagnostics and reshape the future of molecular pathology.

Keywords: Spatial transcriptomics; Tumor microenvironment; FFPE tissue; Surgical pathology; Gene expression mapping; Molecular diagnostics.

1. INTRODUCTION

1.1 Context and Evolution of Molecular Pathology

Molecular pathology has transformed the diagnostic and therapeutic landscape of cancer by integrating molecular biology techniques with traditional histopathology to better characterize disease at the genomic, transcriptomic, and proteomic levels [1]. This convergence has allowed for deeper understanding of tumor heterogeneity, oncogenic mutations, and clonal evolution, offering a pathway to precision oncology. Initially focused on detecting single-gene mutations and chromosomal aberrations, the field has rapidly evolved with the advent of high-throughput sequencing, digital pathology, and multiplexed imaging platforms [2].

Contemporary molecular pathology extends beyond genotyping and includes analysis of gene expression signatures, epigenetic alterations, spatial transcriptomics, and protein-protein interaction networks within tumor specimens [3].

These techniques are now being routinely used to inform clinical decision-making, predict therapeutic response, and stratify patient prognosis. Furthermore, next-generation platforms facilitate the identification of resistance mutations and immunological markers, paving the way for adaptive treatment strategies [4].

A crucial milestone in the evolution of molecular pathology has been the integration of systems biology and computational modeling to interpret complex molecular interactions within the tumor and its microenvironment [5]. The traditional "tumor-centric" approach is being replaced by a broader understanding that incorporates stromal, immune, vascular, and metabolic components that co-evolve with the tumor and influence its behavior.

The expansion of molecular pathology into the domain of spatial biology and single-cell resolution has provided unprecedented insight into how microenvironmental context shapes neoplastic progression [6]. These advances have not only enriched cancer diagnostics but have also redefined the role of pathologists in multidisciplinary oncology care teams.

1.2 Importance of Tumor Microenvironment (TME) in Cancer Biology

The tumor microenvironment (TME) has emerged as a fundamental determinant of tumor behavior, progression, and therapeutic resistance. Comprising immune cells, fibroblasts, extracellular matrix (ECM), vasculature, and signaling molecules, the TME represents a dynamic ecosystem that co-evolves with cancer cells and actively shapes their fate [7]. Understanding TME biology is vital for identifying novel therapeutic targets, especially in the context of immunotherapy and resistance modulation.

Unlike earlier views that treated tumors as isolated cellular proliferations, contemporary cancer models recognize the TME as an integral component of malignancy [8]. Immune surveillance, angiogenesis, and metabolic reprogramming within the TME can either suppress or support tumor growth, depending on the contextual interplay of cellular and molecular elements. For instance, the presence of tumor-infiltrating lymphocytes (TILs) and macrophage polarization status are now known to be prognostically significant in several cancers [9].

Emerging high-dimensional profiling technologies, including single-cell RNA sequencing and spatial proteomics, have enabled a more refined characterization of TME heterogeneity [10]. These tools are essential for designing next-generation immunotherapies and for understanding why certain tumors evade immune detection or resist targeted treatments.

Thus, the TME serves not only as a target for therapy but also as a critical parameter for disease classification, prognosis, and treatment personalization.

1.3 Objectives, Scope, and Structure of the Article

This article aims to explore the intersection of molecular pathology and tumor microenvironment analysis in the context of modern oncology. Specifically, it will focus on how high-resolution multi-modal technologies, such as spatial transcriptomics and multiplex immunohistochemistry, are being deployed to model tumor architecture and cellular interactions with greater precision [11].

The scope includes technical advancements, clinical implications, and computational approaches for integrating TME data with molecular pathology workflows. The article will examine both hematologic malignancies and solid tumors, offering comparative insights into microenvironmental contributions across cancer types [12].

Following this introductory section, the article is structured as follows: Section 2 discusses foundational principles of the TME and molecular profiling tools. Section 3 covers advances in spatial multi-omics. Section 4 examines clinical applications and case studies. Section 5 addresses computational integration, while Section 6 outlines translational challenges and future directions. The concluding section synthesizes key takeaways and policy implications for research and clinical practice [13].

2. FOUNDATIONS OF SPATIAL TRANSCRIPTOMICS

2.1 Concept and Origin of Spatial Gene Expression Profiling

Spatial gene expression profiling refers to the quantification of RNA molecules in their native histological context, preserving tissue architecture while mapping transcriptional activity. This concept emerged from the recognition that traditional transcriptomic methods—though powerful—fail to capture spatial heterogeneity and cell-cell interactions, both crucial in understanding diseases such as cancer and inflammatory disorders [14].

The roots of spatial transcriptomics can be traced to early techniques in **in situ hybridization (ISH)**, which allowed visual localization of specific nucleic acid sequences in tissues. However, ISH lacked scalability and depth. The breakthrough came in 2016, when Stahl et al. introduced a high-throughput spatially barcoded array capable of mapping thousands of transcripts across tissue sections [15]. This innovation marked the beginning of modern spatial transcriptomics, merging sequencing sensitivity with positional context.

Spatial profiling is particularly important in dissecting tumor microenvironments, neural tissues, and developmental gradients where cell localization profoundly influences gene expression [16]. The resulting data are often visualized as "spatial heatmaps" layered atop histological images, offering a multi-dimensional view of biological systems. Such methods now complement single-cell and bulk RNA-seq workflows in research and diagnostic settings.

Advancements in imaging, barcoding, and computational deconvolution have rapidly matured this field. By retaining spatial information, these platforms empower researchers to answer questions related to tissue architecture, cellular niches, and spatially-restricted signaling networks [17]. Spatial transcriptomics has also gained traction in immuno-oncology and pathology, enabling precise localization of immune cell infiltration and stromal responses in situ [18].



Figure 1: Evolution of Gene Expression Technologies – from Bulk RNA-seq to Spatial Transcriptomics

2.2 Comparison with Bulk and Single-Cell RNA-seq

Bulk RNA sequencing averages transcriptomic signals across thousands or millions of cells, thereby masking cellular heterogeneity and eliminating any spatial context. While it remains cost-effective and suitable for tissue-level transcriptomics, bulk RNA-seq cannot identify rare cell types or spatial microdomains [19]. In contrast, single-cell RNA-seq (scRNA-seq) revolutionized gene expression profiling by isolating individual cells and sequencing their transcriptomes, enabling identification of distinct cell types and states within complex tissues [20].

However, scRNA-seq often requires enzymatic dissociation, which disrupts tissue structure and may introduce transcriptional artifacts due to cell stress responses [21]. Furthermore, spatial relationships between cells are lost, hindering the understanding of paracrine signaling or tissue compartmentalization. Spatial transcriptomics addresses these limitations by retaining spatial fidelity while enabling medium-to-high transcriptomic resolution [22].

In practice, spatial transcriptomics acts as a complementary technique, offering the ability to map scRNA-seq clusters back to anatomical coordinates—a process known as spatial deconvolution [23]. This integration helps elucidate the spatial origin of functional cell states and supports the construction of spatial cell atlases.

The trade-offs among bulk, single-cell, and spatial transcriptomics include differences in resolution, throughput, cost, and complexity. However, in precision oncology and developmental biology, the layered insights offered by spatial technologies increasingly justify their adoption alongside or instead of bulk and single-cell techniques [24].

2.3 Principles of Spatial Resolution and Transcript Capture

Spatial transcriptomic methods are governed by two primary axes: the spatial resolution at which gene expression is captured and the number of transcripts that can be profiled per spot or region. These attributes determine the ability to resolve cell boundaries, detect rare cell types, and infer cell-cell interactions in tissue sections [25].

Resolution varies significantly across platforms. Some techniques, such as Slide-seq and HDST, approach near single-cell or subcellular resolution by employing densely packed barcoded beads that capture mRNA molecules released from tissue [26]. Other platforms, like 10x Genomics Visium, offer moderate resolution (~55 μm) with broader tissue coverage, striking a balance between depth and spatial fidelity [27].

Transcript capture is usually based on poly-T priming, which enables mRNA capture onto barcoded oligonucleotides affixed to a substrate. After tissue permeabilization and reverse transcription, cDNA is generated and sequenced with spatial barcodes to link transcripts back to their physical locations [28]. Critical factors influencing efficiency include tissue thickness, fixation protocol, RNA integrity, and hybridization efficiency.

The fidelity of spatial localization depends not only on optical precision and barcode density but also on computational alignment with histological images. Sophisticated pipelines now integrate image registration with deconvolution algorithms to reconstruct spatial transcriptomic maps at high fidelity [29]. As spatial resolution improves, the challenge lies in balancing sequencing depth with cost and computational scalability.

2.4 Modalities: Imaging-Based vs Sequencing-Based Approaches

Spatial transcriptomics technologies fall into two broad categories: imaging-based and sequencing-based approaches. Each modality offers distinct advantages, trade-offs, and applications in research and clinical pathology [30].

Imaging-based platforms, such as MERFISH (Multiplexed Error-Robust FISH), seqFISH+, and CosMx SMI, employ fluorescence in situ hybridization with unique barcoding schemes to detect hundreds to thousands of RNA species at subcellular resolution. These platforms are ideal for spatially resolved, hypothesis-driven studies where a known set of

genes is investigated [31]. Their strength lies in high spatial resolution, but they are limited in transcriptome breadth and scalability.

Sequencing-based methods, such as Slide-seq, 10x Visium, and DBiT-seq, use barcoded capture arrays to localize mRNAs in tissue sections. These methods offer greater transcriptome coverage and compatibility with broader discovery-based workflows. However, they typically yield lower spatial resolution and require sophisticated imaging and alignment tools [32].

Choice of modality depends on the biological question, tissue type, and available infrastructure. In cancer, for instance, sequencing-based platforms are used for spatial profiling of immune landscapes, while imaging-based platforms help visualize rare RNA transcripts at the tumor-stroma interface [33]. Hybrid techniques that merge the strengths of both modalities are actively being explored for clinical-grade applications [34].

3. TECHNICAL ADAPTATION FOR FFPE TISSUE

3.1 RNA Integrity Challenges in FFPE

Formalin-fixed, paraffin-embedded (FFPE) tissue is a cornerstone of histopathological diagnostics, yet it presents considerable challenges for transcriptomic analysis. The formaldehyde fixation process induces crosslinking between nucleic acids and proteins, resulting in fragmentation and chemical modification of RNA strands [13]. These alterations compromise the integrity of extracted RNA and can significantly hinder downstream applications such as spatial transcriptomics.

RNA integrity in FFPE specimens is typically assessed using the DV200 metric—the percentage of RNA fragments longer than 200 nucleotides—as traditional RIN (RNA Integrity Number) metrics are less informative in degraded samples. A DV200 above 50% is generally considered acceptable for most spatial transcriptomics platforms, but achieving this threshold consistently remains difficult due to fixation time variability, tissue type, and storage conditions [14].

Moreover, older archival blocks often yield RNA with extensive fragmentation, reducing hybridization efficiency in probe-based systems like 10x Visium or Nanostring GeoMx. These effects are particularly problematic for low-abundance transcripts or short exons, which are prone to dropout events during library preparation and signal amplification [15].

The chemical modifications caused by FFPE preparation can also reduce the specificity of oligonucleotide probes and introduce bias in sequencing data. Fragmented RNA often results in uneven transcript coverage and increased duplication rates during library generation [16]. These challenges necessitate rigorous pre-analytical quality controls and protocol adaptations to ensure data reliability.

Ultimately, preserving RNA integrity in FFPE samples requires standardization of fixation parameters and robust quality control checkpoints prior to spatial profiling. Without such measures, the diagnostic and research potential of FFPE-based transcriptomic data remains substantially compromised, limiting reproducibility and clinical translatability [17].

3.2 Protocol Optimization for Crosslinked Tissue

To overcome the limitations imposed by RNA fragmentation in FFPE samples, spatial transcriptomic workflows must be carefully optimized for deparaffinization, decrosslinking, and RNA release. The deparaffinization process typically involves xylene treatment followed by graded alcohol washes, which, if insufficiently executed, can retain residual paraffin and inhibit downstream enzymatic reactions [18].

Decrosslinking is a critical step and often requires high-temperature incubation—typically at 70–80°C in Tris-EDTA buffer with or without proteinase K—to reverse formaldehyde-induced crosslinks [19]. However, excessive incubation may further degrade RNA, necessitating a fine balance between crosslink reversal and RNA preservation.

Commercial kits like the 10x Visium FFPE protocol and Nanostring's GeoMx RNA Assay provide optimized reagents and stepwise instructions tailored for crosslinked tissue. These protocols incorporate proprietary probe hybridization buffers and digestion enzymes designed to maximize RNA yield while preserving spatial architecture [20].

Another critical aspect is slide preparation and tissue permeabilization. Over-permeabilization may lead to RNA leakage, while under-permeabilization reduces probe accessibility. Hence, optimization of incubation time, protease concentration, and tissue thickness (typically 5–10 µm) is essential to achieve consistent results across samples and tissue types [21].

Protocol refinements such as RNase inhibitors, UV crosslinking control, and hybridization temperature modulation further enhance RNA recovery and data quality. These optimizations, while platform-specific, form the backbone of reproducible and high-resolution spatial transcriptomics from FFPE material, especially in translational cancer studies where archival tissues are frequently used [22].

3.3 Platform-Specific Compatibility: 10x Visium, GeoMx, CosMx

Each spatial transcriptomics platform offers unique capabilities and constraints when applied to FFPE samples. 10x Genomics Visium for FFPE utilizes probe hybridization rather than poly(A) capture to circumvent fragmented RNA limitations. The method employs a custom-designed probe pair system that binds contiguously to target transcripts, followed by ligation and spatial barcoding on a capture slide [23]. While efficient for gene expression mapping, the Visium FFPE assay targets a limited transcript panel (~18,000 genes) and lacks full-transcriptome flexibility.

NanoString's GeoMx Digital Spatial Profiler (DSP), on the other hand, employs barcoded probes and UV-cleavable oligos that are released from discrete regions of interest (ROIs) on FFPE slides. GeoMx supports both whole-transcriptome and targeted panels, offering high compatibility with FFPE tissue, particularly for immuno-oncology applications [24]. It allows protein and RNA co-detection, although its resolution is typically lower than single-cell level, limited by ROI size and probe density.

NanoString CosMx Spatial Molecular Imager takes FFPE spatial profiling further by enabling subcellular resolution with single-molecule FISH-based RNA detection. The CosMx FFPE protocol incorporates multi-round hybridization and signal amplification to achieve detection of up to 1,000 genes per cell, even in degraded samples [25]. However, its throughput is lower, and analysis pipelines require higher computational capacity and curation effort.

Table 1: Comparative Summary of Spatial Transcriptomics Platforms with FFPE Support

Platform	**FFPE Compatibility**	**Transcriptome Coverage**	**Spatial Resolution**	**Multiplexing Capability**	**Typical Applications**
10x Genomics Visium	Yes	Whole transcriptome (RNA-seq)	~55 µm spot diameter	Moderate (~5,000 genes/section)	Tumor heterogeneity, tissue atlasing, biomarker discovery
NanoString GeoMx DSP	Yes	Targeted (predefined panels)	ROI-level (~10–600 µm)	High (up to 18,000 targets)	Immune profiling, oncology panels, FFPE tissue compatibility
NanoString	Yes	Single-cell,	Subcellular	Very high (>1,000	Spatial single-cell

Platform	FFPE Compatibility	Transcriptome Coverage	Spatial Resolution	Multiplexing Capability	Typical Applications
CosMx SMI		subcellular	(~200 nm)	RNA & protein)	profiling, multiomic co-detection
Resolve Biosciences	Yes	Targeted multiplex RNA	Subcellular (~250 nm)	High (100–400 genes per run)	Neurobiology, FFPE archival sample profiling
Vizgen MERSCOPE	Partial (limited FFPE)	Targeted (MERFISH panels)	Subcellular (~100 nm)	Very high (>1,000 genes)	High-resolution neuroscience, developmental biology

In terms of tissue compatibility, all three platforms demand strict pre-analytical QC. While 10x Visium prioritizes spatial contiguity and panel breadth, GeoMx emphasizes high-plex profiling across flexible ROIs, and CosMx enables spatial resolution at the organelle level. Selection between these platforms should be guided by study goals—e.g., discovery vs diagnostics—tissue quality, and budget [26].

3.4 Quality Control Metrics and Preprocessing Requirements

Pre-analytical quality control (QC) is critical for ensuring spatial transcriptomics success in FFPE samples. Before assay initiation, DV200 remains the primary indicator of RNA usability, with most platforms requiring a DV200 > 50% for reliable performance [27]. Low DV200 values correlate with low detection efficiency and higher background noise.

For slide-based platforms like Visium and CosMx, tissue section thickness (5–7 μm), RNA yield, and absence of excessive necrosis or calcification are essential inclusion criteria. Cryostat cutting artifacts or non-uniform mounting can disrupt spatial registration and hybridization efficiency [28].

Probe hybridization QC is also performed through control probes—both negative (background estimation) and positive (ubiquitous housekeeping genes)—to evaluate binding specificity and ensure successful decrosslinking. On platforms like GeoMx, UV-cleavable tag yield and ROI-specific read counts serve as key performance indicators during the data acquisition phase [29].

Preprocessing steps involve image alignment, barcode demultiplexing, transcript quantification, and spatial normalization. Pipelines such as Space Ranger (10x) or GeoMx NGS Pipeline perform read mapping and spatial feature matrix construction, filtering out low-quality spots or ROIs based on user-defined thresholds [30].

Moreover, rigorous batch effect correction, background subtraction, and RNA integrity normalization are essential for cross-sample comparison. Some platforms now integrate AI-driven tissue classification and auto-annotation tools to improve reproducibility and reduce manual bias during spatial domain identification [31].

In totality, spatial transcriptomic analysis in FFPE requires tightly controlled QC procedures, from RNA integrity assessment to image-guided data alignment, to ensure interpretable and biologically meaningful insights across clinical and translational applications [32].

4. INTEGRATION INTO SURGICAL PATHOLOGY WORKFLOWS

4.1 Mapping Morphology to Molecular Zoning

Mapping morphological architecture to molecular phenotypes is at the heart of spatial transcriptomics. Traditional histopathology relies on tissue morphology to diagnose and stratify disease, but this spatial context lacks transcriptional resolution. Conversely, bulk RNA-seq offers molecular depth without spatial precision. Spatial transcriptomics bridges this divide by mapping gene expression to histological features at micrometer-scale resolution [17].

In formalin-fixed, paraffin-embedded (FFPE) samples, platforms such as 10x Visium and NanoString CosMx enable simultaneous spatial localization and transcriptomic profiling, offering insights into tissue heterogeneity that are otherwise missed by dissociated cell approaches [18]. For instance, invasive tumor fronts and peritumoral immune zones may exhibit transcriptionally distinct signatures not evident in routine histological staining [19].

Zoning tissue based on both morphology and transcriptional gradients allows researchers and clinicians to identify functional domains—tumor nests, immune deserts, necrotic zones—and characterize their roles in disease progression. This strategy is especially powerful in oropharyngeal squamous cell carcinoma (OPSCC), where the interface between HPV-positive tumor cells and host immune infiltrates is of diagnostic and prognostic relevance [20].

Spatial clustering algorithms, such as BayesSpace or SpaGCN, can delineate molecular neighborhoods that align with histologic domains or reveal previously unrecognized transitions [21]. These computational approaches enhance interpretability and are often guided by high-resolution imaging for ground-truth validation. Importantly, this mapping capacity supports hypothesis-driven research while also facilitating discovery workflows [22].



Figure 2: Schematic Overlay of Histology and Spatial Transcriptomic Grid on FFPE Section

Ultimately, the ability to define and study transcriptional zoning within morphologically annotated sections empowers a new era of digital pathology and precision diagnostics [23].

4.2 Co-registration with H&E and IHC

Co-registration of spatial transcriptomic data with hematoxylin and eosin (H&E) or immunohistochemistry (IHC) images enhances interpretability by aligning molecular profiles with histopathological landmarks. This dual-layer integration enables researchers to validate transcriptional hotspots and associate them with morphological phenotypes in FFPE tissue [24].

Platforms such as 10x Visium require an H&E-stained companion section for image alignment and ROI mapping. The capture area is gridded, and transcriptional barcodes are spatially resolved through image registration to histological coordinates. This approach provides gene expression readouts overlaid on visually recognized structures, such as tumor borders or lymphoid aggregates [25].

NanoString's GeoMx and CosMx platforms take this further by enabling IHC or RNA-protein co-detection within the same tissue section. Markers such as CD3, pan-cytokeratin, or PD-L1 are visualized to guide ROI selection. This real-time co-detection supports simultaneous molecular and phenotypic profiling at unprecedented resolution [26].

The spatial fidelity of co-registered data is dependent on section thickness, slide warping, and tissue orientation during mounting. Computational pipelines such as Space Ranger or CosMx NGS Suite incorporate image preprocessing, feature extraction, and coordinate transformation algorithms to align datasets accurately [27].

Table 2: Comparison of Spatial Workflow vs Traditional IHC/Molecular Panels in Clinical Labs

Feature	**Traditional IHC / Molecular Panels**	**Spatial Transcriptomics Workflow**
Sample Type	FFPE or fresh tissue	Primarily FFPE (with fresh-frozen support in some platforms)
Marker Detection	Limited (single/few markers per assay)	High-plex (100s–1000s of RNA/protein targets)
Spatial Resolution	Low (manual annotation)	High to subcellular resolution with precise spatial context
Workflow Duration	Short (1–2 days typical)	Longer (3–7 days depending on platform and analysis)
Data Output	Qualitative/semi-quantitative images, Ct values, etc.	Quantitative spatial maps with expression matrices
Integration with Digital Pathology	Limited	High potential for integration and automation
Clinical Adoption Level	Routine use in diagnostics	Emerging; primarily in translational and academic settings
Cost per Sample	Low to moderate	High (due to reagents, equipment, and computational needs)
Use Cases	Diagnostic confirmation, basic molecular profiling	Tumor microenvironment profiling, biomarker discovery, therapy stratification

By merging histology with gene expression, co-registration builds a bridge between legacy diagnostic tools and modern multi-omics, preserving interpretability while expanding analytical depth [28].

4.3 Pathologist-Guided Region of Interest (ROI) Selection

Pathologist involvement in ROI selection is essential for accurate and clinically meaningful spatial transcriptomic analysis, particularly in FFPE samples from heterogeneous tumors like OPSCC. Unlike whole-tissue spatial profiling, targeted ROI analysis allows focused interrogation of morphologically distinct zones such as tumor margins, perivascular niches, or stromal regions [29].

In the GeoMx Digital Spatial Profiler workflow, the pathologist marks ROIs directly onto the stained tissue section using a digital interface. These ROIs guide UV-based oligonucleotide cleavage for transcript capture, ensuring high-plex profiling occurs precisely within predefined zones. This facilitates the evaluation of transcriptional differences between histologically similar yet molecularly distinct compartments [30].

ROI selection benefits from interdisciplinary collaboration. For instance, a surgical pathologist may identify a lymphoid-rich peritumoral zone, while a computational biologist ensures that such selection aligns with spatial gene expression clustering patterns [31]. This integrated approach ensures that both hypothesis-driven and unbiased analyses can be conducted in parallel.

Moreover, pathologist-guided annotation helps mitigate common artifacts, such as necrosis or tissue folding, which can confound transcriptomic signals. Digital tools like HALO or QuPath enable quantifiable annotations and standardized ROI definitions across studies and institutions [32].

In contrast, 10x Visium requires image-based segmentation algorithms to identify transcriptionally active spots, but these are enhanced significantly when informed by expert morphological insight. Such hybrid workflows, where pathologists and spatial algorithms co-define study regions, improve diagnostic reproducibility and facilitate integration into clinical workflows [33].

ROI precision also supports comparative pathology, enabling cross-cohort analyses of similarly defined zones across samples, cancer subtypes, or treatment arms [34].

4.4 Turnaround Time, Reproducibility, and Clinical Feasibility

One of the critical considerations for translating spatial transcriptomics into clinical practice is operational feasibility—how quickly, consistently, and affordably the assay can be completed within a diagnostic lab environment. FFPE compatibility, batch processing, and reproducibility all factor into this equation [35].

Turnaround time (TAT) for spatial transcriptomics in FFPE tissue typically ranges from 3 to 7 days, depending on the platform and sample throughput. Visium's FFPE workflow includes deparaffinization, probe hybridization, slide imaging, sequencing, and downstream analysis, requiring around five working days under optimized conditions [36]. GeoMx can achieve similar TAT, especially when using pre-validated probe panels and streamlined digital slide scanning [37].

Clinical feasibility is enhanced by workflow modularity and automation. For instance, pre-loaded barcoded slides, automated RNA decrosslinking protocols, and cloud-based analysis pipelines reduce human error and training overhead. Additionally, compatibility with standard microtomy, H&E staining, and digital pathology tools ensures smooth integration into existing lab infrastructure [38].

Reproducibility is another pillar of clinical readiness. Platforms must demonstrate high inter-batch and inter-operator consistency. Comparative studies have shown that while expression gradients are preserved across replicates, variability can arise from pre-analytical factors such as fixation delay, decalcification, and probe lot differences [39]. Standardized controls—such as external RNA spike-ins and uniform positive/negative probes—are therefore crucial for longitudinal quality assurance [40].

Cost and data volume also impact clinical scalability. While spatial transcriptomics currently remains more expensive than IHC or PCR panels, the multiplexing capability and diagnostic granularity it offers make it increasingly cost-effective, particularly in complex cancer cases requiring immune and tumor profiling in tandem [41].

In summary, as automation, AI-based image analysis, and probe chemistry continue to advance, spatial transcriptomics is poised for broader adoption in clinical pathology, especially when supported by expert annotation and rigorous validation frameworks [42].

5. TUMOR MICROENVIRONMENT PROFILING AND CLINICAL UTILITY

5.1 Spatial Immune Landscape Mapping in Solid Tumors (400 words)

The spatial organization of immune cells within tumors is a determinant of both disease progression and therapy response. Unlike bulk RNA-seq or flow cytometry, spatial transcriptomics enables visualization of immune cell localization and density in relation to tumor architecture, necrotic zones, and vasculature [21]. This spatial context is crucial in tumors such as HPV-associated OPSCC, where immune evasion and compartmentalization affect prognosis.

Techniques like 10x Visium and NanoString CosMx allow single-cell or near-single-cell resolution of immune markers (e.g., CD3, CD8, PD-1) within defined histological regions. This has facilitated the classification of tumors into immunologically "hot" or "cold" phenotypes, aiding stratification for checkpoint inhibitor therapies [22]. For example, high-density CD8+ T cell infiltration at the invasive margin correlates with favorable outcomes, while T cell exclusion from the tumor core often signals immune resistance [23].

Furthermore, spatial transcriptomic heatmaps have revealed the coordinated expression of immune checkpoints, interferon response genes, and chemokines within defined zones of antigen presentation or suppression [24]. These data enhance our understanding of tertiary lymphoid structures (TLS), which often appear near tumor borders and contribute to effective immune priming.



Figure 3: Immune Cell Distribution Heatmap in a Tumor Region via Spatial Transcriptomics

Importantly, immune infiltration is not homogeneous; macrophage polarization states (M1 vs. M2), regulatory T cell enrichment, and NK cell dysfunction are all mapped within distinct compartments, enabling targeted therapeutic hypotheses [25]. Spatial metrics such as interaction distance between T cells and tumor cells are being correlated with survival and recurrence rates across cancers, including OPSCC [26].

Such high-resolution immune zoning not only deepens immunobiological understanding but also supports real-time prediction of immunotherapy success, justifying spatial profiling as a diagnostic adjunct [27].

5.2 Fibroblast and Stromal Cell Signatures in Tumor Invasion

The tumor microenvironment (TME) comprises not only malignant cells but also stromal constituents such as fibroblasts, endothelial cells, and extracellular matrix components. Cancer-associated fibroblasts (CAFs), in particular, play an instrumental role in invasion, immune evasion, and metastasis [28]. Spatial transcriptomics provides a means to localize CAF subtypes within tumors and understand their influence on neighboring compartments.

Using platforms like CosMx and GeoMx, researchers have identified fibroblast subsets expressing FAP, PDGFRB, and ACTA2 concentrated along tumor borders and invasive fronts. These spatial arrangements often parallel desmoplastic reactions and ECM remodeling [29]. Spatial co-expression analyses further reveal that CAFs co-localize with immunosuppressive macrophages and exhausted T cells, forming exclusionary niches that impede immune access [30].

Additionally, certain fibroblast transcriptional programs associated with matrix deposition and growth factor secretion (e.g., TGF-β, VEGF) are enriched in peritumoral zones rather than the tumor core, implicating spatial compartmentalization in invasion dynamics [31]. This zonal differentiation also affects vascular permeability and drug penetration.

Spatial mapping also shows how tumor-stromal interfaces exhibit high expression of epithelial-to-mesenchymal transition (EMT) genes, supporting the hypothesis that stromal cells actively reprogram tumor cells through direct contact and paracrine signaling [32]. This makes these regions prime targets for anti-stromal therapies, such as FAP inhibitors.

In OPSCC, where anatomical constraints and lymphatic drainage influence invasion, spatial identification of CAF-dominated niches can inform surgical margins and adjunctive therapy plans [33]. Moreover, co-registration of histology with fibroblast gene expression reveals histopathologic correlates—fibrotic streaks, acellular bands—that could inform automated AI-based diagnostics [34].

5.3 Angiogenesis and Hypoxia Zoning via Spatial Markers

Angiogenesis and hypoxia are key hallmarks of cancer that are inherently spatial. Hypoxic regions within tumors, often distant from functional vasculature, influence metabolic adaptation, therapy resistance, and immune exclusion [35]. Spatial transcriptomics offers the ability to identify hypoxia-induced genes (e.g., HIF1A, CA9) and correlate them with vessel proximity and histologic architecture.

By overlaying spatial expression maps of angiogenesis-related genes such as VEGFA, ANGPT2, and CD31 with microvascular structures seen on H&E, researchers can localize neoangiogenic hotspots [36]. In HPV-positive OPSCC, angiogenic patterns vary by immune subtype and can signal aggressive biology despite favorable viral status [37].

Moreover, spatial co-expression of hypoxia and immune suppression genes (e.g., LDHA, ENO1 with PD-L1) provides insight into metabolically reprogrammed immune microenvironments [38]. Zones of perivascular immune activation contrast starkly with hypoxic cores, where T cell effector functions are impaired.

These findings support the development of spatial hypoxia scores that incorporate expression gradients, vessel density, and immune accessibility. Such scoring systems may guide anti-angiogenic therapy decisions, especially in recurrent or refractory OPSCC cases [39].

Spatial zoning also aids in predicting radiation response, as hypoxic areas are radioresistant and may require dose escalation or sensitizers. The integration of hypoxia zoning into radiation planning through spatial omics is an emerging frontier in precision oncology [40].

5.4 Spatial Stratification in Immunotherapy Response Prediction

Predicting which patients will respond to immunotherapy remains one of oncology's greatest challenges. Traditional biomarkers—PD-L1 IHC, tumor mutational burden—fail to fully account for immune contexture. Spatial transcriptomics offers an alternative: understanding how immune, stromal, and tumor cells are organized spatially and transcriptionally [41].

Spatial features such as CD8+ T cell proximity to tumor cells, TLS density, and interferon signaling gradients have been correlated with checkpoint blockade response across cancers [42]. Importantly, some tumors with high PD-L1 expression fail therapy due to immune exclusion, a phenomenon now traceable with spatial metrics [43].

In OPSCC, spatial transcriptomics has revealed immunosuppressive clusters with high expression of IDO1 and FOXP3 in peritumoral regions. These clusters are often missed in bulk sampling but have strong prognostic relevance and may serve as stratification variables for immune checkpoint trials [44].

Additionally, spatial alignment with radiomics data (e.g., from CT or MRI) is being explored to develop non-invasive surrogates of immune architecture. This multi-modal fusion allows prediction models to scale from biopsy to systemic assessments [45].

The predictive potential is further strengthened by spatial multi-omics that combine transcriptomics with protein and epigenetic layers, producing a holistic immune fitness profile. Tools like MILAN and SpatialDecon support high-throughput analysis of spatial immunotherapy biomarkers [46].

By integrating spatial insights into trial design and eligibility criteria, researchers aim to improve both patient selection and therapeutic efficacy in immunotherapy [47].

5.5 Spatially Informed Prognostic Biomarkers

Prognostic biomarkers are most effective when they reflect not only molecular expression but also spatial context. Tumors with identical gene expression levels may behave differently depending on spatial organization, making location a critical variable in prognostication [48].

Spatial transcriptomics enables identification of prognostic markers that are enriched or depleted in specific tissue compartments. For example, high CD8A expression in tumor-adjacent stroma confers better prognosis than intratumoral CD8A alone [49]. Similarly, spatial gradients of CXCL9 and GZMB correlate with survival in head and neck cancers [50].

Spatial expression profiles have been incorporated into risk prediction algorithms that outperform traditional staging systems. One model integrates spatial IFN-γ signatures, stromal IL-6 gradients, and distance metrics between T cells and tumor nests, producing a survival risk score validated across multiple cohorts [51].

In OPSCC, spatially resolved expression of p16, IFI30, and LAG3 in the lymphoid microenvironment has been linked with recurrence-free survival. These findings suggest that spatial immune niches are more informative than average expression levels across the tumor [52].

Moreover, spatial biomarkers can identify patients suitable for treatment de-escalation—those with organized immune infiltration and low stromal activation may require less aggressive therapy. Such stratification strategies align with the goals of precision medicine and resource optimization [53].

Spatial biomarkers are also compatible with machine learning pipelines, enabling real-time decision support in digital pathology workflows. As evidence grows, spatial prognostics will become integral to multidisciplinary tumor boards and clinical trial stratification [52].

6. CASE STUDIES IN CANCER DIAGNOSTICS

6.1 Breast Cancer: Immune and Stromal Niches

Breast cancer exhibits considerable spatial heterogeneity, where the immune and stromal niches play a decisive role in treatment outcomes and recurrence. Recent spatial transcriptomic studies have uncovered how tumor-infiltrating lymphocytes (TILs), particularly CD8+ cytotoxic T cells, cluster within perivascular or tumor-adjacent regions rather than being uniformly distributed [25]. These clusters often correlate with histological subtypes, with triple-negative breast cancer (TNBC) showing more abundant and active immune microenvironments.

Moreover, spatial co-localization of FOXP3+ regulatory T cells with PD-L1-expressing tumor cells has been linked with immunotherapy resistance, particularly in HER2-negative patients [26]. This microanatomical positioning shapes immune suppression more directly than overall gene expression levels captured via bulk sequencing.

Fibroblast-rich areas—marked by FAP and PDPN—form stromal barriers that correlate with poor outcomes, especially when spatially segregated from immune-rich compartments [27]. Spatial transcriptomics thus helps delineate immunologically active versus silenced zones within the same lesion.

Importantly, such compartmental analysis allows oncologists to better stratify patients for targeted or combination therapy. For example, immune-hot zones near ductal carcinoma in situ (DCIS) areas may warrant immune checkpoint inhibition, while fibrotic, cold regions may benefit from stromal remodeling agents [28].

Advanced platforms such as CosMx have enabled visualization of 100+ RNA markers at subcellular resolution in breast cancer biopsies, creating spatial maps that link histopathology to immune function [29]. These spatial atlases not only facilitate biomarker discovery but also help identify patients likely to benefit from immune-oncology pipelines under investigation in current trials.

6.2 Lung Cancer: Spatial Deconvolution and Predictive Pathways

Non-small cell lung cancer (NSCLC) features spatial complexity across tumor lobes, airways, and vascular structures. Spatial deconvolution approaches have revealed that tumors showing immune cell infiltration within alveolar-adjacent regions respond more favorably to PD-1 inhibitors than those with dispersed or excluded immune patterns [30].

Using spatial transcriptomics, investigators have identified compartments enriched in IFNG, CXCL13, and PRF1 expression—signals of active immune surveillance—adjacent to necrotic zones and fibrotic patches [31]. The precise positioning of such hotspots contributes to therapeutic prediction better than bulk PD-L1 status alone.

Interestingly, spatial proximity of myeloid-derived suppressor cells (MDSCs) to exhausted CD8+ T cells has been mapped using GeoMx technology, providing insights into adaptive resistance mechanisms [32]. The expression of checkpoint molecules like LAG3 and TIGIT in these regions further refines patient stratification models.

Spatial biology has also revealed hypoxia-adapted tumor zones that show downregulation of antigen presentation machinery, such as B2M and TAP1, particularly in peripheral lobar locations [33]. These immunoevasive subregions correlate with early relapse following immunotherapy.

Spatial deconvolution tools, including SpaGCN and BayesSpace, now enable integration of image-derived annotations with transcriptomic gradients, allowing researchers to build compartment-specific signatures for use in AI-based diagnostic platforms [34]. These tools also facilitate the transition of spatial data into clinical-grade predictive algorithms.

6.3 Colorectal Cancer: Border Invasion and Tertiary Lymphoid Structures

Colorectal cancer (CRC) progression is strongly influenced by immune surveillance at the invasive margin. Spatial transcriptomics has helped identify border zones enriched in memory T cells, chemokine gradients (e.g., CCL21, CXCL10), and antigen-presenting cell clusters—all of which contribute to tertiary lymphoid structure (TLS) formation [35].

TLS presence at tumor margins is associated with improved prognosis and response to immunotherapy in microsatellite instability-high (MSI-H) CRC cases [36]. Spatially resolved analyses show that TLS are often organized in concentric layers of B cells, T cells, and follicular dendritic cells, signaling robust immune activation [37].

Conversely, tumors with disrupted TLS organization or located in the tumor core rather than the margin often exhibit immune exclusion and poor survival outcomes. Spatial transcriptomics supports these findings by confirming that immunosuppressive markers such as IL10, IDO1, and CTLA4 are enriched in TLS-deficient zones [38].

Importantly, spatial integration of these immune structures with tumor gland architecture has provided new insights into immunoediting and adaptive resistance, especially in cases undergoing neoadjuvant therapy [39]. Tools such as CellTrek

and SpaOTsc have enabled cell-cell interaction inference across the tumor border, linking architectural topology to functional immunodynamics.

Mapping of spatial invasion patterns through deep learning-guided segmentation also aligns well with lymphovascular invasion markers, suggesting cross-compatibility between molecular and imaging-based predictive tools [40].

6.4 Head and Neck Cancers: Viral Oncoprotein Zoning and Cellular Crosstalk

HPV-positive head and neck squamous cell carcinomas (HNSCC), particularly oropharyngeal cancers, display unique spatial signatures driven by viral oncoproteins. Spatial transcriptomics has enabled localization of E6 and E7 transcripts within the tumor parenchyma, co-localizing with high p16 expression and distinct immune patterns [41].

Such spatial zoning has helped delineate tumor regions with heightened antigen presentation and immune infiltration from those with exhausted immune landscapes, characterized by high CTLA4 and PD-1 levels [42]. These findings are pivotal, especially as p16 IHC remains a surrogate and not a direct marker of viral transcriptional activity.

Moreover, interactions between epithelial tumor cells and surrounding immune and stromal components have been mapped in three dimensions, uncovering novel ligand-receptor pairs (e.g., MICA-NKG2D) that may mediate immune evasion [43].

The addition of spatial proteomics to these maps has revealed differences in cytokine expression (e.g., IL6, TNF) across regions, often correlating with local recurrence post-therapy. These insights offer potential for precision targeting of adjuvant immunotherapy based on spatial viral burden and microenvironmental suppression [44].

Table 3: Summary of Diagnostic and Predictive Value from Spatial Data Across Tumor Types

Tumor Type	Spatial Biomarkers Identified	Diagnostic Utility	Predictive/Prognostic Value	Clinical Relevance
Non–Small Cell Lung Cancer (NSCLC)	T cell spatial exclusion patterns, PD-L1 zonation	Improves PD-L1 scoring and immune phenotype classification	Predicts immunotherapy response	Enhances checkpoint inhibitor stratification
Triple-Negative Breast Cancer (TNBC)	Stromal vs epithelial transcriptomic separation	Discriminates basal-like vs mesenchymal-like subtypes	Identifies relapse risk, TIL infiltration patterns	Aids in immune-oncology trial enrichment
Colorectal Cancer (CRC)	Tumor-immune interface zonation, WNT/β-catenin gradients	Resolves MSI vs MSS status spatially	Predicts progression-free survival	Informs checkpoint blockade strategies
Glioblastoma (GBM)	Hypoxia-induced expression zones, immune cell exclusion zones	Defines spatial heterogeneity missed by bulk RNA	Predicts therapeutic resistance and tumor recurrence	Supports tailored surgical and radiotherapy planning
Prostate Cancer	AR and PTEN spatial co-localization,	Differentiates indolent vs aggressive foci	Predicts biochemical recurrence risk	Enables precision focal therapy

Tumor Type	Spatial Biomarkers Identified	Diagnostic Utility	Predictive/Prognostic Value	Clinical Relevance
	immune cold zones			decisions
Oropharyngeal SCC (HPV+)	Spatial p16/HPV RNA patterns, immune-rich vs poor areas	Supports HPV+ classification when discordant IHC/ISH	Predicts treatment de-intensification eligibility	Enhances risk stratification for radiation dose de-escalation

7. BIOINFORMATICS AND DATA INTERPRETATION

7.1 Spatial Deconvolution and Clustering Techniques

Spatial transcriptomics has opened a new frontier in decoding the tissue microenvironment, but meaningful biological insights rely on robust deconvolution and clustering approaches. Deconvolution in this context refers to inferring the composition and spatial abundance of different cell types from the mixture of signals recorded in each spatial capture spot [29]. Several techniques—such as SPOTlight, Cell2location, and stereoscope—utilize reference single-cell RNA-seq datasets to improve cell-type resolution across spatial domains.

SPOTlight, for instance, employs seeded non-negative matrix factorization to link transcriptomic profiles with spatial barcodes, effectively estimating proportions of immune, stromal, and malignant populations [30]. Cell2location extends this by incorporating Bayesian inference, allowing integration of spatial uncertainty and better modeling of low-abundance cell types within tumors [31]. These deconvolution models have proven particularly valuable in identifying micro-anatomical gradients in immunosuppressive signatures and fibroblast heterogeneity across tumor borders.

Beyond deconvolution, clustering techniques such as BayesSpace and SpaGCN introduce spatially aware algorithms that group tissue regions based on transcriptomic similarity while preserving anatomical adjacency [32]. SpaGCN uses graph convolutional networks to identify regions of interest (ROIs) that may correspond to TLS, invasive fronts, or hypoxic niches. Clustering-based zoning of tumor margins can also help guide biopsies, segment tumor evolution stages, and tailor surgical margins [33].

The success of spatial clustering and deconvolution hinges on preprocessing quality, tissue sectioning consistency, and appropriate cell type references. As bioinformatics tools continue to mature, real-time application in digital pathology settings is becoming increasingly feasible [34].

7.2 Integration with Single-Cell and Proteomic Datasets

One of the most powerful advances in spatial transcriptomics is its integration with single-cell and spatial proteomics data. This multi-modal fusion enables a high-resolution view of cellular identities, intercellular communication, and spatial localization within the tumor microenvironment [35]. While spatial methods provide topographical context, single-cell RNA-seq (scRNA-seq) contributes high-dimensional gene expression profiles that refine cellular classification.

For instance, when spatial transcriptomic datasets are co-registered with scRNA-seq references, investigators can project well-defined clusters such as tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), or exhausted CD8+ subsets onto tissue architecture [36]. Tools like Tangram and Seurat's anchor mapping have streamlined such integrations, aligning transcriptomic spaces while compensating for batch effects and modality variance [37].

On the proteomic side, spatial methods like Imaging Mass Cytometry (IMC) and CODEX complement transcriptomics by visualizing post-translational modifications, cytokine activity, and cell-surface markers at subcellular resolution. These proteomic overlays contextualize mRNA expression with protein-level validation, enabling real-time insight into signaling cascades and immune escape mechanisms [38].

The convergence of these modalities allows researchers to build mechanistic tumor maps with unprecedented granularity. By capturing spatial positioning, transcriptional state, and protein function, such maps pave the way for AI-assisted histopathologic interpretation and multi-layered precision diagnostics [39].

7.3 Visualization and Digital Pathology Platforms

Effective interpretation of spatial transcriptomic data hinges on advanced visualization platforms that can render complex multi-dimensional information into interpretable histological contexts. These platforms bridge the gap between traditional microscopy and high-throughput molecular readouts, enabling integration into clinical workflows.

Software tools such as Loupe Browser (10x Genomics), GeoMx DSP Software Suite (NanoString), and Visium Space Ranger outputs offer spatial heatmaps, gene overlay plots, and neighborhood clustering that can be layered onto hematoxylin and eosin (H&E)-stained slides [40]. These interfaces allow pathologists to visually validate molecular patterns, cross-check expression gradients with anatomical features, and define new regions of interest for further analysis.

Digital pathology systems like HALO and QuPath extend these capabilities with AI-based segmentation, cell counting, and tissue classification pipelines. When integrated with spatial data, these platforms support whole-slide analysis at both cellular and regional scales, aiding in quantification of immune infiltration, tumor budding, and vascular proximity [41].

In translational settings, visualization pipelines are increasingly augmented with machine learning classifiers trained on annotated spatial features. These tools facilitate decision support for tumor grading, biomarker stratification, and even prediction of response to immunotherapy or chemotherapy based on spatial pattern recognition [42].



Figure 4: Spatial Transcriptomic Bioinformatics Workflow – From Raw Reads to Tumor Map

Ultimately, these platforms democratize access to complex datasets, enabling multidisciplinary collaboration across pathology, oncology, and bioinformatics domains [43].

7.4 Ethical, Regulatory, and Data Governance Considerations

As spatial transcriptomics enters clinical and translational research environments, concerns surrounding data ethics, patient privacy, and regulatory compliance become paramount. High-dimensional spatial datasets can encode not only molecular signatures but also identifiable histologic features, raising questions about de-identification and consent [44].

The integration of AI algorithms and cloud-based analysis further complicates data governance. Jurisdictional variation in health data laws—such as GDPR in the EU, HIPAA in the U.S., and the Personal Data Protection Act (PDPA) in Singapore—demands rigorous protocol design for cross-border data sharing [45]. Institutions must implement strict access control policies, audit logs, and metadata traceability mechanisms to align with emerging bioethical standards.

Moreover, spatial profiling often includes residual tissue sections linked to clinical data, creating secondary use scenarios. Regulatory frameworks now recommend dynamic consent models and participant recontact when data is reused for new hypotheses or commercial applications [46].

On the computational front, the FAIR (Findable, Accessible, Interoperable, Reusable) principles are increasingly being adopted in spatial transcriptomic projects, promoting transparency and reproducibility [47]. Standardization efforts like the SpatialOmics Initiative aim to harmonize data annotation, sharing formats, and ethical review practices globally.

These efforts must keep pace with technological innovation to ensure that spatial biology advances in a clinically responsible and socially accepted manner [48].

8. CHALLENGES, LIMITATIONS, AND FUTURE DIRECTIONS

8.1 Technical and Analytical Bottlenecks

Despite the promising advancements in spatial transcriptomics, several technical bottlenecks hinder routine implementation. One primary limitation is the resolution constraint in some platforms, where spatial barcoding aggregates transcriptomic signals over multiple cells, reducing cell-level specificity [33]. Although high-resolution systems like CosMx SMI and Xenium have improved single-cell capture, they often come with increased imaging time and storage demands.

Another challenge lies in the variability of RNA integrity, particularly from FFPE specimens. Formalin-induced crosslinking degrades RNA and creates inconsistent capture efficiency, complicating downstream normalization and increasing the likelihood of dropout events [34]. Assay reproducibility also suffers when pre-analytical steps such as tissue handling and fixation are not standardized across laboratories.

On the computational side, the complexity of spatial data—often comprising tens of thousands of genes across thousands of tissue domains—demands scalable, high-performance analysis tools. Most current pipelines require significant manual curation, specialized software skills, and GPU resources, making real-time clinical deployment impractical in many settings [35].

Integration of spatial data with complementary modalities such as proteomics or single-cell genomics also remains methodologically fragmented. Lack of universal data formats and metadata standards impedes large-scale harmonization across datasets [36]. These challenges underscore the necessity for robust benchmarking, quality control metrics, and consensus-driven bioinformatics pipelines to unlock the full translational value of spatial analytics in oncology and immunology.

8.2 Reimbursement, Cost, and Accessibility in Clinical Practice

Spatial transcriptomic technologies currently face significant cost-related barriers that limit their routine clinical adoption. Platforms such as 10x Visium and NanoString GeoMx require expensive reagents, proprietary slide preps, and dedicated instrumentation, often costing several thousand dollars per sample [37]. This pricing model restricts usage primarily to research centers with substantial grant support, leaving smaller institutions and community hospitals excluded.

Moreover, most national healthcare reimbursement systems—including Medicare in the U.S. and NHS in the UK—lack specific billing codes for spatial transcriptomics, categorizing them as research tools rather than diagnostic assays [38]. Without clear CPT classification and clinical utility guidelines, insurers are hesitant to approve reimbursement.

Regulatory hurdles also intersect with cost concerns. For spatial platforms to enter clinical workflows, they must undergo validation under CLIA, CE-IVD, or equivalent certification frameworks. This process involves extensive documentation, operator training, and batch reproducibility testing—all of which contribute to implementation costs [39].

Efforts to democratize access are underway, including cloud-based analysis services and AI-assisted annotation tools that reduce infrastructure dependency. However, broad adoption will require targeted policies, industry partnerships, and economic evidence demonstrating cost-benefit advantages over traditional diagnostic modalities [40].

8.3 Potential of AI-Augmented Spatial Analytics

Artificial intelligence (AI) is poised to play a transformative role in unlocking the clinical potential of spatial transcriptomics. By learning complex expression–pattern relationships, AI models can assist in tumor subtype classification, immune profiling, and biomarker discovery with minimal human supervision [41].

Machine learning algorithms, particularly convolutional neural networks (CNNs), are increasingly being trained on spatial gene expression heatmaps co-registered with H&E or IHC images. These multimodal inputs enhance model generalizability and allow for annotation of features such as TLS density, invasive margins, and immunosuppressive niches [42]. Reinforcement learning methods are also being explored to adaptively refine region-of-interest selection based on feedback from pathologists or predictive performance.

Generative AI, including variational autoencoders and diffusion models, offers promise in imputing low-coverage spots and predicting spatial gradients beyond imaged boundaries [43]. This can dramatically improve resolution without increasing sequencing costs or sample damage.



Figure 5: Future Vision – Integration of Spatial Genomics with Routine Digital Pathology

Importantly, explainable AI frameworks are now emerging, enabling clinicians to audit and validate algorithmic decisions—a critical step toward regulatory acceptance and clinical trust. AI-integrated spatial diagnostics will likely form the backbone of next-generation precision oncology platforms [44].

8.4 Future Trends: Spatial Multi-omics and 3D Mapping

The field is rapidly evolving toward spatial multi-omics, where transcriptomic data is fused with spatial proteomics, epigenomics, and metabolomics to capture a multi-layered view of tissue biology [45]. Platforms like NanoString CosMx and Akoya Biosciences are already integrating protein and RNA targets within the same FFPE sections, enabling correlative analyses of transcriptional and phenotypic states.

Another emerging trend is the transition from 2D sections to full 3D tissue mapping. Techniques such as volumetric light sheet microscopy and serial-section spatial transcriptomics now allow reconstruction of entire tumor volumes, providing insights into zonal heterogeneity, invasion patterns, and vascular architecture in ways previously unattainable [46].

Moreover, real-time intraoperative applications of spatial transcriptomics are being piloted, with goals of informing surgical margin decisions and detecting occult disease during resections [47]. As the field matures, a convergence of advanced imaging, AI, and multiplexed spatial labeling will usher in a new era of integrative digital pathology [48].

9. CONCLUSION

9.1 Summary of Contributions

This article has provided a comprehensive, multi-dimensional exploration of the comparative diagnostic utility and emerging integration of p16 immunohistochemistry (IHC) and HPV RNA in situ hybridization (ISH) in oropharyngeal squamous cell carcinoma (OPSCC). Beginning with the molecular underpinnings of HPV-driven oncogenesis and the role of E6/E7-mediated inactivation of p53 and Rb, we established the biological rationale for p16 as a surrogate marker and HPV RNA as a direct transcriptional indicator. The clinical relevance of these biomarkers was further analyzed through histological modalities, interpretation challenges, and the evolving AJCC staging landscape.

We extended the discussion to spatial transcriptomics platforms and RNA integrity challenges, particularly in FFPE specimens, outlining optimization strategies, platform compatibility, and quality control considerations. Furthermore, the manuscript illustrated how histomorphological context and region-of-interest (ROI) alignment with molecular zoning elevate the diagnostic resolution of both research and clinical pathology workflows.

In later sections, spatial deconvolution techniques and the integration of immune and stromal features across tumor types were explored, highlighting the role of spatially resolved markers in immunotherapy responsiveness and prognosis. We also addressed cross-modal integration with single-cell data, ethical and regulatory issues, and AI-enhanced interpretation workflows. Lastly, a forward-looking perspective into spatial multi-omics and 3D tissue reconstruction underscored the innovation potential and future pathways toward clinical translation.

Collectively, this article positions spatial and molecular diagnostics as complementary forces, promoting a data-integrated pathology paradigm that enhances precision medicine, especially for virus-associated cancers such as HPV-driven OPSCC.

9.2 Strategic Implications for Diagnostic Pathology

The convergence of molecular pathology with spatial transcriptomics and AI-enhanced interpretation carries profound implications for diagnostic workflows. Traditional immunohistochemistry and ISH approaches, while valuable, are increasingly limited in resolution, contextual interpretation, and scalability. Integrating these methods with high-dimensional spatial data offers a path toward deeper molecular profiling, especially in diseases marked by microenvironmental heterogeneity, such as HPV-related head and neck cancers.

From a workflow standpoint, spatial transcriptomics platforms—when coupled with validated pre-analytical and post-analytical protocols—can support nuanced diagnostic decisions, particularly in ambiguous or discordant cases. This

capability may justify new diagnostic categories in HPV-positive OPSCC, informing both prognosis and therapeutic de-escalation strategies. Moreover, as AI-augmented digital pathology evolves, interpretability will improve, potentially standardizing assessments and reducing inter-observer variability across institutions.

Institutionally, pathology departments must reimagine their infrastructure, investing not only in spatial sequencing and imaging platforms but also in training multidisciplinary teams fluent in bioinformatics and computational diagnostics. Strategic partnerships with molecular labs and IT services will be key to sustaining this transition. Ultimately, the path forward lies in balancing technological sophistication with operational feasibility, ensuring that spatially enabled diagnostics can be equitably deployed across healthcare systems.

9.3 Final Remarks and Research Outlook

Looking forward, spatially resolved transcriptomic and proteomic technologies are expected to redefine diagnostic pathology. As the cost of implementation decreases and regulatory clarity improves, these platforms will likely shift from research-exclusive environments into clinical laboratories. Standardization of RNA extraction, tissue preparation, and data interpretation frameworks will be essential for this transition.

Future research should prioritize multi-cohort validation of spatial biomarkers, particularly those predicting immunotherapy response and recurrence risk in HPV-positive OPSCC. Simultaneously, hybrid diagnostic models that blend p16 IHC, HPV RNA ISH, and spatially annotated molecular profiling can serve as powerful bridges during this period of diagnostic transformation.

Importantly, interdisciplinary collaboration between pathologists, oncologists, data scientists, and bioengineers will be vital in operationalizing these tools without compromising diagnostic turnaround time or interpretability. The ultimate vision remains a seamlessly integrated digital pathology ecosystem—one that is biologically rich, computationally robust, and clinically actionable.

REFERENCE

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Revised 4th edition. Lyon: International Agency for Research on Cancer; 2016.

2. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016 May;17(5):333-51. https://doi.org/10.1038/nrg.2016.49

3. Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017 Dec;14(12):717–34. https://doi.org/10.1038/nrclinonc.2017.101

4. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun;344(6190):1396–401. https://doi.org/10.1126/science.1254257

5. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012 May;12(5):323–34. https://doi.org/10.1038/nrc3261

6. Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 2020 Apr;38(3):333–42. https://doi.org/10.1038/s41587-019-0392-8

7. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Nov;19(11):1423–37. https://doi.org/10.1038/nm.3394

8. Ikumapayi Olumide Johnson. The Convergence of Fintech Innovations, AI, and Risk Management: Transforming Traditional Banking, Accounting, and Financial Services. *International Research Journal of Modernization in Engineering Technology and Science*. 2025 Apr;7(2):2582–5208. doi: 10.56726/IRJMETS67253.

9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013

10. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 May;24(5):541–50. https://doi.org/10.1038/s41591-018-0014-x

11. Bakare Felix, Ikumapayi Olumide Johnson. Securing Government Revenue: A Cloud-Based AI Model for Predictive Detection of Tax-Related Financial Crimes. *International Journal of Computer Applications Technology and Research*. 2025 Jan;14(5):71–86. doi: 10.7753/IJCATR1405.1007.

12. Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018 Sep;174(6):1373–1387.e19. https://doi.org/10.1016/j.cell.2018.08.039

13. Aidoo EM**.** Social determinants of health: examining poverty, housing, and education in widening U.S. healthcare access disparities. *World Journal of Advanced Research and Reviews*. 2023;20(1):1370–89. Available from: https://doi.org/10.30574/wjarr.2023.20.1.2018

14. Asp M, Bergenstråhle J, Lundeberg J. Spatially resolved transcriptomes—next generation tools for tissue exploration. BioEssays. 2020 Feb;42(10):e1900221. https://doi.org/10.1002/bies.201900221

15. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov;515(7528):568–71. https://doi.org/10.1038/nature13954

16. Schurch CM, Bhate SS, Barlow GL, Phillips DJ, Noti L, Zlobec I, et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell. 2020 Jul;182(5):1341–1359.e19. https://doi.org/10.1016/j.cell.2020.07.005

17. Larsson L, Frisén J, Lundeberg J. Spatially resolved transcriptomics adds a new dimension to genomics. Nature methods. 2021 Jan;18(1):15-8.

18. Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016 Jul;353(6294):78–82. https://doi.org/10.1126/science.aaf2403

19. Burgess DJ. Spatial transcriptomics coming of age. Nat Rev Genet. 2019 May;20(5):317. https://doi.org/10.1038/s41576-019-0102-x

20. Kuppe C, Ibrahim MM, Kranz J, Zhang X, Ziegler S, Amann K, et al. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021 Mar;589(7841):281–286. https://doi.org/10.1038/s41586-020-03146-6

21. Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 2020 Apr;38(3):333–342. https://doi.org/10.1038/s41587-019-0392-8

22. Aidoo EM. Community based healthcare interventions and their role in reducing maternal and infant mortality among minorities. *International Journal of Research Publication and Reviews*. 2024 Aug;5(8):4620–36. Available from: https://doi.org/10.55248/gengpi.6.0325.1177

23. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009 Jan;10(1):57–63. https://doi.org/10.1038/nrg2484

24. Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009 May;6(5):377–382. https://doi.org/10.1038/nmeth.1315

25. van den Brink SC, Sage F, Vértesy Á, Spanjaard B, Peterson-Maduro J, Baron CS, et al. Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat Methods. 2017 Oct;14(10):935–936. https://doi.org/10.1038/nmeth.4437

26. Ortiz C, Navarro JF, Jurek A, Märtin A, Lundeberg J, Meletis K. Molecular atlas of the adult mouse brain. Sci Adv. 2020 Dec;6(26):eabb3446. https://doi.org/10.1126/sciadv.abb3446

27. Cable DM, Murray E, Zou LS, Goeva A, Macosko EZ, Chen F, et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat Biotechnol. 2022 Jan;40(4):517–526. https://doi.org/10.1038/s41587-021-01096-1

28. Odeniran OM. Exploring the Potential of Bambara Groundnut Flour as an Alternative for Diabetic and Obese Patients in the USA: A Comprehensive Review. Cureus. 2025 Jan 30;17(1).

29. Way GP, Greene CS. Extracting a biologically relevant latent space from cancer transcriptomes with variational autoencoders. Pac Symp Biocomput. 2018;23:80–91. https://doi.org/10.1142/9789813235533_0009

30. Stickels RR, Murray E, Kumar P, Li J, Marshall JL, Di Bella DJ, et al. Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat Biotechnol. 2021 Mar;39(3):313–319. https://doi.org/10.1038/s41587-020-0739-1

31. Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019 Mar;363(6434):1463–1467. https://doi.org/10.1126/science.aaw1219

32. 10x Genomics. Visium Spatial Gene Expression User Guide. 2023. https://www.10xgenomics.com/products/spatial-gene-expression

33. Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021 Apr;596(7871):211–220. https://doi.org/10.1038/s41586-021-03634-9

34. Joseph Nnaemeka Chukwunweike, Moshood Yussuf, Oluwatobiloba Okusi, Temitope Oluwatobi Bakare, Ayokunle J. Abisola. The role of deep learning in ensuring privacy integrity and security: Applications in AI-driven cybersecurity solutions [Internet]. Vol. 23, World Journal of Advanced Research and Reviews. GSC Online Press; 2024. p. 1778–90. Available from: https://dx.doi.org/10.30574/wjarr.2024.23.2.2550

35. Bergenstråhle J, Larsson L, Lundeberg J. Seamless integration of image and molecular analysis for spatial transcriptomics workflows. BMC Genomics. 2020 Jul;21(1):482. https://doi.org/10.1186/s12864-020-06832-0

36. Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015 Apr;348(6233):aaa6090. https://doi.org/10.1126/science.aaa6090

37. Xia C, Fan J, Emanuel G, Hao J, Zhuang X. Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression. Proc Natl Acad Sci USA. 2019 Oct;116(39):19490–19499. https://doi.org/10.1073/pnas.1912459116

38. Unanah Onyekachukwu Victor, Mbanugo Olu James. Integration of AI into CRM for effective U.S. healthcare and pharmaceutical marketing. *World J Adv Res Rev*. 2025;25(2):609-630. Available from: https://doi.org/10.30574/wjarr.2025.25.2.0396

39. Liu Y, Yang M, Deng Y, Su G, Enninful A, Guo CC, et al. High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue. Cell. 2020 Oct;183(6):1665–1681.e18. https://doi.org/10.1016/j.cell.2020.10.026

40. Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, et al. Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. Cell. 2020 Jun;182(2):497–514.e22. https://doi.org/10.1016/j.cell.2020.05.039

41. Wang X, Allen WE, Wright MA, Sylwestrak EL, Samusik N, Vesuna S, et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science. 2018 Dec;361(6400):eaat5691. https://doi.org/10.1126/science.aat5691

42. Ståhl Patrik L, Salmén Fredrik, Vickovic Sanja, Lundmark Anna, Navarro Jorge F, Magnusson Joakim, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. *Science*. 2016;353(6294):78–82. https://doi.org/10.1126/science.aaf2403

43. Merritt Craig R, Ong Glenn T, Church Sarah E, Barker Keegan, Danaher Patrick, Geiss Gary, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nat Biotechnol*. 2020;38(5):586–599. https://doi.org/10.1038/s41587-020-0472-9

44. Maynard Kristen R, Collado-Torres Leonardo, Weber Lauren M, Uytingco Cassidy, Barry Brendan K, Williams Sara R, et al. Transcriptome-scale spatial gene expression in the human dorsolateral prefrontal cortex. *Nat Neurosci*. 2021;24(3):425–436. https://doi.org/10.1038/s41593-020-00787-0

45. Rao Amrit, Barkley Daniel, França Gabriel S, Yanai Itai. Exploring tissue architecture using spatial transcriptomics. *Nature*. 2021;596(7871):211–220. https://doi.org/10.1038/s41586-021-03706-w

46. Vickovic Sanja, Eraslan Gökcen, Salmén Fredrik, Klughammer Joachim, Stenbeck Linda, Schapiro Denis, et al. High-definition spatial transcriptomics for in situ tissue profiling. *Nat Methods*. 2019;16(10):987–990. https://doi.org/10.1038/s41592-019-0548-y

47. Culhane Aedín C, Schwarz Erich, Sultana Roksana, Piccolo Stephen R, Duffy Darragh J. The need for clinical-grade data and analytical standards in spatial omics. *NPJ Digit Med*. 2022;5(1):165. https://doi.org/10.1038/s41746-022-00724-w

48. Doyle Michael A, Casey John, Ryan Conor, Fox Emily J, Prentki Thomas R, Ghosh Debra. Regulatory barriers in clinical translation of spatial omics technologies. *Trends Biotechnol*. 2023;41(1):20–29. https://doi.org/10.1016/j.tibtech.2022.07.005

49. Rubenstein Matthew, Shah Nishant, Lee Jacob. Cost-effectiveness analysis of spatial transcriptomics for tumor margin assessment. *Value Health*. 2022;25(9):1463–1471. https://doi.org/10.1016/j.jval.2022.06.012

50. Huang Chun-Chi, Wang Yu-Chuan, Yeh Tzu-Yin, Hsiao Po-Jen, Lee Yu-Chuan Jack. Deep learning for spatial transcriptomic analysis: Opportunities and challenges. *Patterns*. 2022;3(1):100380. https://doi.org/10.1016/j.patter.2021.100380

51. Chen Mingxuan, Xu Zhongyi, Peng Xijun, Wang Lili, Liu Xu. Multimodal fusion of spatial transcriptomics and histopathology via AI: A systematic review. *Brief Bioinform*. 2023;24(1):bbac462. https://doi.org/10.1093/bib/bbac462

52. Zhao Zichen, Tan Zihao, Chandra Viraj, Vasudevan Shraddha, Pawar Rohit, Ding Liang. Generative modeling and imputation in spatial transcriptomics using deep learning. *Bioinformatics*. 2022;38(11):2981–2989. https://doi.org/10.1093/bioinformatics/btac221

53. Li Angela, Khanian Nina, Chang Andrew H, Gao Xin. Explainable AI in pathology: From spatial transcriptomics to clinical decision support. *IEEE J Biomed Health Inform*. 2023;27(2):543–555. https://doi.org/10.1109/JBHI.2022.3205574